中國高科(600730.SH):子公司擬掛牌轉讓萬順達89.33%股權
格隆匯7月1日丨中國高科(600730.SH)公佈,為聚焦主業、優化公司資產結構和資源配置,持續提升公司核心競爭力,公司全資子公司武漢國信擬通過公開掛牌渠道掛牌轉讓所持有的萬順達89.33%股權。本次交易完成後,公司及公司下屬子公司不再持有萬順達股權,公司不再將其納入合併報表範圍。結合評估基準日後已發生的萬順達以物抵債、萬順達向股東分紅事項,在評估價基礎上扣除其以物抵債中所涉抵債資產的評估值、萬順達向股東分紅的金額後,確定武漢國信轉讓其所持有萬順達89.33%股權的掛牌價格為1,694.31萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.